Back to search

Boston University

Targeting endothelial dysfunction in systemic sclerosis: a comparison of current and emerging therapeutics

Abstract

dc:description.abstract

Systemic sclerosis is an autoimmune connective tissue disorder that despite the development of new therapeutics, retains poor long-term outcomes. The progression of the disease involves various organ systems leading to the development of severe complications that deteriorate patient’s quality of life and survival rates. The pathogenesis of the disease is extraordinarily complex and arises from disruptions across multiple systems. Current research emphasizes the role of early initial endothelial injury in the manifestation of systemic sclerosis. Addressing endothelial dysfunction has been an appealing target for the development of new therapeutics. Specifically, research has focused on the endothelin-1 pathway, the nitric oxide pathway, and the prostacyclin pathway for developing new medications. This research has yielded endothelin-1 receptor antagonists, phosphodiesterase-5 inhibitors, guanylate cyclase stimulators, and prostacyclin analogues as the major classes of medications used to treat this disease. Current therapeutics prove effective in preventing and slowing further endothelial damage but offer little ability to reverse fibrosis related damage. Complications such as pulmonary arterial hypertension, digital ulcers, are Raynaud’s phenomenon are most directly addressed by endothelial targeted therapies. However, other complications such as interstitial lung disease are not addressed by these types of medications. Consequently, the current approach to treatment relies on combining therapies to target complications from multiple avenues. Efficacy of existing therapeutics are similar across the board, however patients may prove individually more receptive to certain therapies. Personalized care that addresses patient’s individual susceptibility through autoantibody and genetic analysis prove effective in achieving better prognoses.

Degree

thesis:*
Name thesis:degree_name
Master of Science
Level thesis:degree_level
masters
Discipline thesis:degree_discipline
Medical Sciences
Grantor
Boston University
Year dc:date.issued
2026

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Kassis, Zack
Advisors dc:contributor.advisor
  • Offner, Gwynneth D
  • Symes, Karen

Subjects

dc:subject × 4

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/2144/53497

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Kassis, Zack. Targeting endothelial dysfunction in systemic sclerosis: a comparison of current and emerging therapeutics. masters thesis, Boston University, 2026. https://hdl.handle.net/2144/53497